Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline

Gilead is making headlines with its planned acquisition of Tubulis GmbH, a Germany-based company, for a maximum of five billion dollars. This strategic move aims to enhance Gilead's cancer drug offerings, especially as it faces challenges from expiring patents and a dip in COVID-19 related product sales.

Go to News Site